| abstract |
The invention features a series of heterocyclic derivatives that suppress tumor necrosis factor alpha (TNF-α) -induced necroptosis. The heterocyclic compounds of the present invention are described by formulas (I) and (Ia)-(Ie) and are shown to suppress TNF-α induced necroptosis in FADD deficient mutants of human Jurkat T cells. The invention further features a pharmaceutical composition in which the compound of the invention is a major component. The compounds and compositions of the invention can also be used to treat disorders where necrotosis appears to play a substantial role. [Selection figure] None |